Pandemic threats of the H1N1 influenza virus have drawn attention to developing a universal vaccine against circulating and future strains of this virus. An immunoinformatics study was conducted to identify conserved peptides containing CD4+ and CD8+ T-cell epitopes from all the hemagglutinin (HA) and neuraminidase (NA) protein sequences available until February 2013 to cover the seasonal as well as the pandemic strains of the H1N1 virus. In the present study, six different immunoinformatics prediction programs were used in order to define the epitopes. Five conserved peptides of HA and six of NA protein were obtained that contained overlapping CD4+ and CD8+ T-cell epitopes. These identified peptides have a binding affinity for a large number of major histocompatibility complex (MHC) alleles. WHGSNRPWVSF of NA protein is a new peptide whose T-cell response has not been previously reported. Population coverage studies have shown that these peptide fragments have the capacity to induce a potent immune response among individuals from different populations around the world. Hence, these HA and NA peptides may be considered as interesting candidates for vaccine design.
Get full access to this article
View all access options for this article.
References
1.
AltschulSF, GishW, MillerW, MyersEW, and LipmanD. Basic local alignment search tool. J Mol Biol, 1990; 215:403–410.
2.
AssarssonE, BuiHH, SidneyJ, et al.Immunomic analysis of the repertoire of T-cell specificities for influenza A virus in humans. J Virol, 2008; 82:12241–12251.
3.
BabonJA, CruzJ, OrphinL, et al.Genome-wide screening of human T-cell epitopes in influenza A virus reveals a broad spectrum of CD4(+) T-cell responses to internal proteins, hemagglutinins, and neuraminidases. Hum Immunol, 2009; 70:711–721.
4.
Ben-YedidiaT. Multimeric-001: BiondVax's universal flu vaccine. Interview by Duc Le. Expert Rev Vaccines, 2010; 9:241–242.
5.
BrownDM, RománE, and SwainSL. CD4 T cell responses to influenza infection. Semin Immunol, 2004; 16:171–177.
6.
BrusicV, and AugustJT. The changing field of vaccine development in the genomics era. Pharmacogenomics, 2004; 5:597–600.
7.
BuiHH, SidneyJ, DinhK, SouthwoodS, NewmanMJ, and SetteA. Predicting population coverage of T-cell epitope-based diagnostics and vaccines. BMC Bioinformatics, 2006; 7:153.
8.
BulloughPA, HughsonFM, SkehelJJ, and WileyDC. Structure of influenza haemagglutinin at the pH of membrane fusion. Nature, 1994; 371:37–43.
9.
CusickMF, WangS, and EckelsDD. In vitro responses to avian influenza H5 by human CD4 T cells. J Immunol, 2009; 183:6432–6441.
10.
DohertyPC, TophamDJ, TrippRA, CardinRD, BrooksJW, and StevensonPG. Effector CD4+ and CD8+ T-cell mechanisms in the control of respiratory virus infections. Immunol Rev, 1997; 159:105–117.
11.
DuvvuriVR, Marchand-AustinA, EshaghiA, PatelSN, LowDE, and GubbayJB. Potential T cell epitopes within swine-origin triple reassortant influenza A (H3N2) variant virus which emerged in 2011: an immunoinformatics study. Vaccine, 2012; 30:6054–6063.
12.
EdgarRC. MUSCLE: a multiple sequence alignment method with reduced time and space complexity. BMC Bioinformatics, 2004; 5:113.
13.
FlowerDR. 2009. Vaccines: data driven prediction of binders, epitopes and immunogenicity: 167–215. Bioinformatics for Vaccinology, John Wiley & Sons, Ltd, Chichester, United Kingdom.
14.
GaleottiF, MassariM, D'AlessandroR, et al.Risk of Guillain–Barré syndrome after 2010–2011 influenza vaccination. Eur J Epidemiol, 2013; 28:433–344.
15.
GeX, GebeJA, BollykyPL, et al.Peptide–MHC cellular microarray with innovative data analysis system for simultaneously detecting multiple CD4 T-cell responses. PLoS One, 2010; 5:e11355.
16.
Gonzalez-GalarzaFF, ChristmasS, MiddletonD, and JonesAR. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acid Research, 2011; 39:D913–D919.
17.
GuptaSK, SrivastavaM, AkhoonBA, et al.Identification of immunogenic consensus T-cell epitopes in globally distributed influenza-A H1N1 neuraminidase. Infect Genet Evol, 2011; 11:308–319.
18.
GurungRB, PurdieAC, BeggDJ, and WhittingtonRJ. In silico screened Mycobacterium avium subsp. paratuberculosis (MAP) recombinant proteins upregulated under stress conditions are immunogenic in sheep. Vet Immunol Immunopathol, 2012; 149:186–196.
19.
HackettCJ, HorowitzD, WysockaM, and EisenlohrLC. Immunogenic peptides of influenza virus subtype N1 neuraminidase identify a T-cell determinant used in class II major histocompatibility complex-restricted responses to infectious virus. J Virol, 1991; 65:672–676.
20.
HeinyAT, MiottoO, SrinivasanKN, et al.Evolutionarily conserved protein sequences of influenza a viruses, avian and human, as vaccine targets. PLoS One, 2007; 2:e1190.
21.
HuangP, YuS, WuC, and LiangL. Highly conserved antigenic epitope regions of hemagglutinin and neuraminidase genes between 2009 H1N1 and seasonal H1N1 influenza: vaccine considerations. J Transl Med, 2013; 11:47.
22.
JohnsonNP, and MuellerJ. Updating the accounts: global mortality of the 1918–1920 “Spanish” influenza pandemic. Bull Hist Med, 2002; 76:105–115.
23.
KwongJC, VasaPP, CampitelliMA, et al.Risk of Guillain–Barré syndrome after seasonal influenza vaccination and influenza health-care encounters: a self-controlled study. Lancet Infect Dis, 2013; 13:769–776.
24.
LarsenMV, LundegaardC, LamberthK, BuusS, LundO, and NielsenM. Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction. BMC Bioinformatics, 2007; 8:424.
25.
LiQ, SunX, LiZ, et al.Structural and functional characterization of neuraminidase-like molecule N10 derived from bat influenza A virus. Proc Natl Acad Sci U S A, 2012; 109:18897–18902.
26.
MatrosovichMN, MatrosovichTY, GrayT, RobertsNA, and KlenkHD. Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol, 2004; 78:12665–12667.
27.
McElhaneyJE, XieD, HagerWD, et al.T cell responses are better correlates of vaccine protection in the elderly. J Immunol, 2006; 176:6333–6339.
28.
MiottoO, HeinyA, TanTW, AugustJT, and BrusicV. Identification of human-to-human transmissibility factors in PB2 proteins of influenza A by large-scale mutual information analysis. BMC Bioinformatics, 2008; 9Suppl 1:S18.
29.
NaylorPH, EganJE, and BerinsteinNL. Peptide based vaccine approaches for cancer—a novel approach using a WT-1 synthetic long peptide and the IRX-2 immunomodulatory regimen. Cancers (Basel), 2011; 3:3991–4009.
30.
NielsenM, and LundO. NN-align. An artificial neural network-based alignment algorithm for MHC class II peptide binding prediction. BMC Bioinformatics, 2009; 10:296.
31.
NielsenM, LundegaardC, and LundO. Prediction of MHC class II binding affinity using SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics, 2007; 8:238.
32.
OvsyannikovaIG, JacobsonRM, and PolandGA. Variation in vaccine response in normal populations. Pharmacogenomics, 2004; 5:417–427.
33.
ParidaR, ShailaMS, MukherjeeS, ChandraNR, and NayakR. Computational analysis of proteome of H5N1 avian influenza virus to define T cell epitopes with vaccine potential. Vaccine, 2007; 25:7530–7539.
34.
ParkerKC, BednarekMA, and ColiganJE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol, 1994; 152:163–175.
35.
PatronovA, and DoytchinovaI. T-cell epitope vaccine design by immunoinformatics. Open Biol, 2013; 3:120139.
36.
PaulWE, and BenacerrafB. Functional specificity of thymus-dependent lymphocytes. Science, 1977; 195:1293–1300.
37.
PicaN, and PaleseP. Toward a universal influenza virus vaccine: prospects and challenges. Annu Rev Med, 2013; 64:189–202.
38.
PowellTJ, StruttT, ReomeJ, et al.Priming with cold-adapted influenza A does not prevent infection but elicits long-lived protection against supralethal challenge with heterosubtypic virus. J Immunol, 2007; 178:1030–1038.
39.
RammenseeH, BachmannJ, EmmerichNP, BachorOA, and StevanovićS. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics, 1999; 50:213–219.
40.
RudolphW, and Ben YedidiaT. A universal influenza vaccine: where are we in the pursuit of this “Holy Grail”?. Hum Vaccin, 2011; 7:10–11.
41.
SchanenBC, De GrootAS, MoiseL, et al.Coupling sensitive in vitro and in silico techniques to assess cross-reactive CD4(+) T cells against the swine-origin H1N1 influenza virus. Vaccine, 2011; 29:3299–3309.
42.
ShtyryaYA, MochalovaLV, and BovinNV. Influenza virus neuraminidase: structure and function. Acta Naturae, 2009; 1:26–32.
43.
SinghH, and RaghavaGP. ProPred: prediction of HLA-DR binding sites. Bioinformatics, 2001; 17:1236–1237.
44.
SkehelJJ, BayleyPM, BrownEB, et al.Changes in the conformation of influenza virus hemagglutinin at the pH optimum of virus-mediated membrane fusion. Proc Natl Acad Sci U S A, 1982; 79:968–972.
45.
SomvanshiP, SinghV, and SethPK. Prediction of epitopes in hemagglutinin and neuraminidase proteins of influenza A virus H5N1 strain: a clue for diagnostic and vaccine development. OMICS, 2008; 12:61–69.
46.
SquiresRB, NoronhaJ, HuntV, et al.Influenza research database: an integrated bioinformatics resource for influenza research and surveillance. Influenza Other Respi Viruses, 2012; 6:404–416.
47.
SwainSL, DuttonRW, and WoodlandDL. T cell responses to influenza virus infection: effector and memory cells. Viral Immunol, 2004; 17:197–209.
48.
TanPT, HeinyAT, MiottoO, et al.Conservation and diversity of influenza A H1N1 HLA-restricted T cell epitope candidates for epitope-based vaccines. PLoS One, 2010; 5:e8754.
49.
TongS, LiY, RivaillerP, et al.A distinct lineage of influenza A virus from bats. Proc Natl Acad Sci U S A, 2012; 109:4269–4274.
50.
TrojanA, UrosevicM, HummerjohannJ, GigerR, SchanzU, and StahelRA. Immune reactivity against a novel HLA-A3-restricted influenza virus peptide identified by predictive algorithms and interferon-gamma quantitative PCR. J Immunother, 2003; 26:41–46.
51.
WangL, ZhangH, CompansRW, and WangBZ. Universal influenza vaccines—a short review. J Immunol Clin Res, 2013; 1:1003–1009.
52.
World Health Organization global alert response update 112. 2010. Available at www.who.int/csr/don/2010_08_06/en/index.html. (accessed April, 2014).
53.
YangJ, JamesEA, HustonL, DankeNA, LiuAW, and KwokWW. Multiplex mapping of CD4 T cell epitopes using class II tetramers. Clin Immunol, 2006; 120:21–32.
54.
ZhaoK, ShiX, ZhaoY, et al.Preparation and immunological effectiveness of a swine influenza DNA vaccine encapsulated in chitosan nanoparticles. Vaccine, 2011; 29:8549–8556.
